1224288-95-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Oxo-4,5-dihydropyrazolo[1,5-a]pyriMidine-3-carbonitrile is used as a synthetic building block for the creation of various pharmaceutical compounds. Its unique structure and reactivity contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Oxo-4,5-dihydropyrazolo[1,5-a]pyriMidine-3-carbonitrile serves as a key intermediate in the synthesis of agrochemicals, potentially leading to the development of novel pesticides or other agricultural chemicals that can improve crop protection and yield.
Used in Research and Development:
5-Oxo-4,5-dihydropyrazolo[1,5-a]pyriMidine-3-carbonitrile is utilized as a subject of study in research and development labs. Its distinctive structural features and chemical reactivity make it an interesting compound for exploring new reactions and applications, which could lead to advancements in organic chemistry and related fields.
Used in Drug Discovery and Development:
Due to its potential biological activity and therapeutic potential, 5-Oxo-4,5-dihydropyrazolo[1,5-a]pyriMidine-3-carbonitrile is employed as a target in drug discovery and development processes. Researchers aim to harness its properties to create new pharmaceutical agents that could address unmet medical needs.

Upstream product

• 1001-26-9 ethyl 3-ethoxyacrylate 
• 16617-46-2 3-amino-4-cyano-2H-pyrazole 
• 5941-55-9 ethyl 3-ethoxyacrylate 

Downstream Products

• 478081-98-0 N-(3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)-N-ethylacetamide 
• 1224288-92-9 5-chloropyrazolo[1,5-a]pyrimidine-3-carbonitrile 
• 1260846-28-3 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK

This invention relates to inhibitors of NTRK comprising a pyrazolo[1,5-4]pyrimidine-3-carbonitrile structure. They are active against wild-type NTRK and its resistant mutants.

FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS

The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR3C(O)NR4R5, —C≡CC(O)NR4R5, or

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Synthetic studies connected with the preparation of N-[3-(3- cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide, a zaleplon regioisomer

N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethyl-acetamide, a principal impurity of zaleplon, is prepared by Suzuki-Miyaura cross coupling reaction of the corresponding boronic acid and/or boronates with 5-chloropyrazolo[1,5-a]pyrimidin-3-carbonitrile (7). Various methods of preparation of both components are described, as well as approaches based on the final modification of the 5-(3-aminophenyl)-pyrazolo[1,5-a]pyrimidine-3- carbonitrile moiety prepared by Suzuki-Miyaura cross coupling. All the prepared compounds were unambiguouesly identified by NMR techniques. Spectral characteristics (IR, UV, MS) of these compounds are also given.